Krystal Income Tax Expense from 2010 to 2024

KRYS Stock  USD 182.29  4.19  2.35%   
Krystal Biotech Income Tax Expense yearly trend continues to be comparatively stable with very little volatility. Income Tax Expense will likely drop to about 1.9 M in 2024. From the period from 2010 to 2024, Krystal Biotech Income Tax Expense quarterly data regression had r-value of  0.38 and coefficient of variation of  318.31. View All Fundamentals
 
Income Tax Expense  
First Reported
2016-06-30
Previous Quarter
477 K
Current Value
2.6 M
Quarterly Volatility
1.5 M
 
Covid
Check Krystal Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Krystal Biotech's main balance sheet or income statement drivers, such as Net Interest Income of 23.8 M, Interest Income of 23.8 M or Depreciation And Amortization of 5.3 M, as well as many indicators such as Price To Sales Ratio of 72.59, Dividend Yield of 0.0 or PTB Ratio of 4.11. Krystal financial statements analysis is a perfect complement when working with Krystal Biotech Valuation or Volatility modules.
  
Check out the analysis of Krystal Biotech Correlation against competitors.
For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.

Latest Krystal Biotech's Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of Krystal Biotech over the last few years. It is Krystal Biotech's Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Krystal Biotech's overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Slightly volatile
   Income Tax Expense   
       Timeline  

Krystal Income Tax Expense Regression Statistics

Arithmetic Mean2,754,294
Geometric Mean0.00
Coefficient Of Variation318.31
Mean Deviation4,172,429
Median0.00
Standard Deviation8,767,306
Sample Variance76.9T
Range37M
R-Value0.38
Mean Square Error71T
R-Squared0.14
Significance0.17
Slope739,338
Total Sum of Squares1076.1T

Krystal Income Tax Expense History

20241.9 M
2023M
202234 M
20212.7 M
20201.6 M
2019-3 M
20182.1 M

About Krystal Biotech Financial Statements

Krystal Biotech shareholders use historical fundamental indicators, such as Income Tax Expense, to determine how well the company is positioned to perform in the future. Although Krystal Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in Krystal Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on Krystal Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Income Tax ExpenseM1.9 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Krystal Stock Analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.